• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-Xa Activity in Elderly Xabans-Treated Patients With Atrial Fibrillation.

作者信息

Samoš Matej, Bolek Tomáš, Škorňová Ingrid, Stančiaková Lucia, Urban Lukáš, Staško Ján, Galajda Peter, Kubisz Peter, Mokáň Marián

机构信息

Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.

Department of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.

出版信息

Am J Ther. 2020 Sep/Oct;27(5):e507-e509. doi: 10.1097/MJT.0000000000001014.

DOI:10.1097/MJT.0000000000001014
PMID:31356346
Abstract
摘要

相似文献

1
Anti-Xa Activity in Elderly Xabans-Treated Patients With Atrial Fibrillation.老年接受Xa因子抑制剂治疗的房颤患者的抗Xa活性
Am J Ther. 2020 Sep/Oct;27(5):e507-e509. doi: 10.1097/MJT.0000000000001014.
2
Interaction Between Direct Factor Xa Inhibitors and Digoxin.直接凝血因子Xa抑制剂与地高辛之间的相互作用。
Am J Ther. 2019 Sep/Oct;26(5):e649-e652. doi: 10.1097/MJT.0000000000000851.
3
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.亚洲心房颤动患者的真实世界利伐沙班和阿哌沙班血药浓度。
Clin Pharmacol Ther. 2020 Jan;107(1):278-286. doi: 10.1002/cpt.1601. Epub 2019 Sep 14.
4
Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban.老年房颤患者服用低剂量阿哌沙班时阿哌沙班高血药浓度的预测因素。
Eur J Clin Pharmacol. 2021 Nov;77(11):1757-1758. doi: 10.1007/s00228-021-03135-8. Epub 2021 May 20.
5
Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.常规护理中利伐沙班和阿哌沙班血浆浓度的患者间差异。
Can J Cardiol. 2017 Aug;33(8):1036-1043. doi: 10.1016/j.cjca.2017.04.008. Epub 2017 Apr 24.
6
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.采用低分子肝素校准的抗因子 Xa 测定法来评估阿哌沙班和利伐沙班的浓度。
Int J Lab Hematol. 2022 Feb;44(1):163-167. doi: 10.1111/ijlh.13692. Epub 2021 Sep 15.
7
Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.直接口服因子 Xa 抑制剂治疗的房颤患者的血小板聚集：一项初步研究。
J Cardiovasc Pharmacol. 2017 Oct;70(4):263-266. doi: 10.1097/FJC.0000000000000516.
8
Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.三种口服因子 Xa 抑制剂的微剂量鸡尾酒，以评估与潜在肇事药物的药物相互作用。
Clin Pharmacokinet. 2019 Sep;58(9):1155-1163. doi: 10.1007/s40262-019-00749-1.
9
Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.质子泵抑制剂是否会改变接受 Xabans 治疗的房颤患者的治疗后抗 Xa 活性？一项初步研究。
J Thromb Thrombolysis. 2019 Jan;47(1):140-145. doi: 10.1007/s11239-018-1748-5.
10
Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.阿哌沙班与利伐沙班治疗心房颤动患者的有效性和安全性
Ann Intern Med. 2020 Apr 7;172(7). doi: 10.7326/P20-0003. Epub 2020 Mar 10.

引用本文的文献

1
Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?心房颤动患者的个体化直接口服抗凝治疗：口服抗凝治疗的未来？
J Clin Med. 2022 Oct 28;11(21):6369. doi: 10.3390/jcm11216369.
2
Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?阿托伐他汀治疗是否会改变华法林治疗的心房颤动患者的抗 Xa 活性？
Pharmacol Res Perspect. 2021 May;9(3):e00730. doi: 10.1002/prp2.730.